Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLT NASDAQ:DRUG NASDAQ:GLUE NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLTApplied Therapeutics$0.52+6.4%$0.44$0.30▼$10.62$75.46M2.052.53 million shs776,278 shsDRUGBright Minds Biosciences$39.26+1.0%$33.37$0.94▼$79.02$275.12M-6.1349,037 shs22,943 shsGLUEMonte Rosa Therapeutics$4.87+1.4%$4.94$3.50▼$12.40$301.57M1.42589,251 shs332,013 shsSCPHscPharmaceuticals$5.51+0.1%$4.78$1.94▼$6.28$293.42M0.35588,663 shs1.49 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLTApplied Therapeutics0.00%-4.24%+11.80%+38.40%-92.23%DRUGBright Minds Biosciences0.00%-6.76%+15.61%+41.59%+3,567.92%GLUEMonte Rosa Therapeutics0.00%+4.58%+0.21%+3.45%-22.20%SCPHscPharmaceuticals0.00%-0.36%+6.38%+42.86%+8.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLTApplied Therapeutics4.0669 of 5 stars3.33.00.04.72.41.70.6DRUGBright Minds Biosciences2.5559 of 5 stars3.62.00.00.03.52.50.0GLUEMonte Rosa Therapeutics2.689 of 5 stars3.31.00.00.02.71.71.9SCPHscPharmaceuticals3.777 of 5 stars3.03.00.04.21.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLTApplied Therapeutics 2.50Moderate Buy$6.101,064.12% UpsideDRUGBright Minds Biosciences 3.13Buy$83.25112.06% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33215.18% UpsideSCPHscPharmaceuticals 2.00Hold$12.00117.98% UpsideCurrent Analyst Ratings BreakdownLatest APLT, DRUG, GLUE, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold8/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLTApplied Therapeutics$460K164.05N/AN/A$0.49 per share1.07DRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AGLUEMonte Rosa Therapeutics$177.99M1.69N/AN/A$3.63 per share1.34SCPHscPharmaceuticals$36.33M8.08N/AN/A$0.27 per share20.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLTApplied Therapeutics-$105.62M-$0.45N/AN/AN/AN/A-354.24%-144.16%11/6/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/AGLUEMonte Rosa Therapeutics-$72.70M$0.3613.56N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)Latest APLT, DRUG, GLUE, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/13/2025Q2 2025APLTApplied Therapeutics-$0.17-$0.15+$0.02-$0.15$0.42 millionN/A8/7/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLTApplied TherapeuticsN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLTApplied TherapeuticsN/A1.941.94DRUGBright Minds BiosciencesN/A86.6486.64GLUEMonte Rosa TherapeuticsN/A7.167.16SCPHscPharmaceuticals3.863.853.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLTApplied Therapeutics98.31%DRUGBright Minds Biosciences40.52%GLUEMonte Rosa Therapeutics79.96%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipAPLTApplied Therapeutics1.60%DRUGBright Minds Biosciences42.66%GLUEMonte Rosa Therapeutics6.50%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLTApplied Therapeutics30144.01 million141.71 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableGLUEMonte Rosa Therapeutics9061.76 million57.75 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableAPLT, DRUG, GLUE, and SCPH HeadlinesRecent News About These CompaniesApis Capital Advisors LLC Grows Holdings in scPharmaceuticals, Inc. $SCPHSeptember 2 at 9:19 AM | marketbeat.comMannKind diversifies pipeline with $360M buySeptember 2 at 5:33 AM | pacbiztimes.comPKingdon Capital Management L.L.C. Buys 200,000 Shares of scPharmaceuticals, Inc. $SCPHSeptember 1 at 6:11 AM | marketbeat.comH.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)August 31 at 10:51 AM | finance.yahoo.comVelan Capital Investment Management LP Makes New Investment in scPharmaceuticals, Inc. $SCPHAugust 31 at 7:15 AM | marketbeat.comMaxim Group Reaffirms Hold Rating for scPharmaceuticals (NASDAQ:SCPH)August 27, 2025 | marketbeat.comMaxim Group Downgrades scPharmaceuticals (NASDAQ:SCPH) to HoldAugust 27, 2025 | americanbankingnews.comscPharmaceuticals downgraded to Hold from Buy at MaximAugust 26, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...August 26, 2025 | tmcnet.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHAugust 26, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of ShareholdersAugust 26, 2025 | globenewswire.comStonepine Capital Management LLC Has $914,000 Stock Holdings in scPharmaceuticals, Inc. $SCPHAugust 26, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at Craig-HallumAugust 25, 2025 | msn.comCT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M dealAugust 25, 2025 | hartfordbusiness.comHMannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M dealAugust 25, 2025 | fiercepharma.comFSCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKindAugust 25, 2025 | globenewswire.comSCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to ShareholdersAugust 25, 2025 | businesswire.comShareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public ShareholdersAugust 25, 2025 | businesswire.comMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung DiseasesAugust 25, 2025 | globenewswire.comscPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Down 36.1% in JulyAugust 21, 2025 | marketbeat.comscPharmaceuticals receives Notices of Allowance from USPTO for SCP-111August 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?By Leo Miller | August 8, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025APLT, DRUG, GLUE, and SCPH Company DescriptionsApplied Therapeutics NASDAQ:APLT$0.52 +0.03 (+6.35%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Bright Minds Biosciences NASDAQ:DRUG$39.26 +0.38 (+0.97%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Monte Rosa Therapeutics NASDAQ:GLUE$4.86 +0.07 (+1.35%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.scPharmaceuticals NASDAQ:SCPH$5.50 +0.01 (+0.09%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Alphabet’s Resurgence: It's Now a Clear Market Leader Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
